The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Toxicity outcomes of anti-BCMA therapy in R/R MM: bispecific T-cell engagers vs belantamab mafodotin
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, introduces a retrospective comparison of toxicity outcomes observed when treating patients with relapsed/refractory (R/R) multiple myeloma (MM) with anti-BCMA bispecific T-cell engagers (TCEs) versus the antibody-drug conjugate (ADC) belantamab mafodotin. Although treatment with bispecific antibodies is associated with a higher response rate, there is a greater risk of infections which must be treated with intravenous immunoglobulins. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: GSK
Honoraria: GSK, Janssen, BMS, AbbVie, Roche
Research Funding: GSK
Current Employment: University College London Hospitals NHS Foundation Trust
